GlassScriptPhysician profile
Suresh Nayak
NPI 1730184946
$536,265.51
in general payments reported to CMS, 2019-2025
13 companies · $100K in 2025
The $100K reported for 2025 was more than what 97% of Orthopaedic Surgery providers received nationally (typical 2025 total: $569).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $151K · 2020: $48K · 2021: $17K · 2022: $77K · 2023: $70K · 2024: $73K · 2025: $100K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $172K · Travel and Lodging: $43K · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $24K · Food and Beverage: $3,321.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $172,397.50 |
| Travel and Lodging | $43,094.18 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $24,400.00 |
| Food and Beverage | $3,320.63 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Stryker Corporation | $480,534.40 | 2019-2025 | Mako, Ortholoc 2 Lapifuse, Triathlon |
| Heron Therapeutics, INC. | $43,333.08 | 2020-2025 | Zynrelef, Aponvie |
| Vertex Pharmaceuticals Incorporated | $11,656.96 | 2024-2025 | |
| Orthalign INC | $289.10 | 2021 | |
| Ferring Pharmaceuticals INC. | $138.22 | 2019-2023 | Euflexxa |
| Pacira Therapeutics, INC. | $118.54 | 2019-2021 | |
| Depuy Synthes Sales INC. | $42.85 | 2024 | Va-Lcp |
| Pfizer INC. | $42.26 | 2024 | |
| Wright Medical Technology, INC. | $28.66 | 2019 | |
| Medtronic, INC. | $27.84 | 2025 | Inceptiv |
| Smith+Nephew, INC. | $26.43 | 2021-2022 | |
| Orthofix Medical, INC. | $13.86 | 2021 | |
| Sanofi-Aventis U.S. LLC | $13.31 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$239,995.68 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Suresh Nayak listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.